Partnering to Transform
the Future of Care
At Daiichi Sankyo, we partner to achieve two key outcomes: deliver breakthrough medicines that transform standards of care and make a real impact for the people who rely on us.
We pursue breakthrough science in areas where our expertise runs deepest, with oncology as our core focus. We also explore emerging platforms and research technologies with the potential to expand therapeutic possibilities for patients and complement our internal pipeline.
Business Development
We seek bold science that builds on our strengths in oncology, complements our internal pipeline, and expands what’s possible through emerging platforms and technologies. Our integrated BD model brings together search & evaluation, transactions, alliance management and strategic initiatives to create a seamless experience for partners advancing differentiated assets and platforms.
Open Innovation
We recognize that meaningful ideas can emerge from anywhere, and we are committed to creating clear, accessible pathways for innovators to engage with our scientists. Through our open innovation programs, we welcome proposals for collaborative research and early scientific exploration. Our aim is to spark discovery, advance cutting-edge science, and help shape the next generation of therapeutic possibilities.
Tell us about your science.
Please submit your non-confidential licensing or alliance proposal for consideration